Status
Conditions
Treatments
About
This initiative supports a quality improvement effort evaluating the use of strategies (including technology-based decision support, referral to a virtual GDMT team, and general educational tools/resources for clinicians and patients) to improve use of guideline-directed therapeutics known to lower cardiovascular (CV) events among patients with cardiovascular diseases of heart failure, atrial fibrillation and type 2 diabetes (T2D)/ASCVD with a specific focus on underserved populations and those with a history of health care disparities.
Full description
TRANSFORM3 is a Quality Improvement initiative conducted in parallel to the current TRANSFORM CVRiD study and aligned with its goals of using a real-world population study to enable the American College of Cardiology Foundation ("ACCF") to better identify impactful ways to improve guideline directed medical therapy for patients. TRANSFORM3 is focused on improving GDMT use in underserved patients and patients with a history of health care disparities who have one or more of the following: heart failure, atrial fibrillation, and ASCVD/Type 2 diabetes.
There is a significant disconnect between increasing availability of effective and safe therapeutics that significantly reduce CV event risk in patients with Heart Failure, T2D and ASCVD, and Atrial Fibrillation-and clear guideline recommendations endorsing these therapies-but very low adoption in clinical practice with the majority of eligible patients that are most likely to benefit from these therapies not receiving them. A high proportion of patients have more than one of these conditions further reducing the chances of receiving optimal guideline directed medical therapy and avoiding the CV events they are designed to prevent.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥18 years
Personal access to a computer and/or Smartphone for app download
Heart Failure (reduced and preserved ejection fraction) AND/OR
Atrial Fibrillation with CHA2DS2-VASc score greater than or equal to 2 in men and greater than or equal to 3 in women AND/OR
T2D and ASCVD, defined as follows:
Exclusion criteria
All patients
Heart Failure patients:
Atrial Fibrillation patients:
Primary purpose
Allocation
Interventional model
Masking
750 participants in 3 patient groups
Loading...
Central trial contact
Lindsey C Hill; Shilpa Patel
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal